002004.SZ
华邦健康
SZSE · Basic Materials · C 制造业 · CN
CNY 4.47
−0.67%Aug 19, 2026, 11:06 UTC
Huabang Health announced its first-half 2026 results: revenue of 5.91 billion yuan, down 0.59% year-on-year; net profit attributable to shareholders of 319 million yuan, down 17.79% year-on-year; non-GAAP net profit of 300 million yuan, down 13.69% year-on-year.
Source:Aug 19, 2026, 11:06 UTC
Huabang Health announced a cash dividend of 1 yuan per 10 shares (tax included), based on total share capital of 1.973 billion shares after excluding 7.0665 million repurchased shares from the repurchase account.
Source:Jul 31, 2026, 08:09 UTC
Huabang Health's wholly-owned subsidiary Chongqing Huabang Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Ibrutinib Tablets approved by the National Medical Products Administration, with specifications of 0.14g and 420mg, registered as chemical drug category 3, applicable for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and other conditions.
Source:Jul 21, 2026, 09:07 UTC
Huabang Health's wholly-owned subsidiary Shenyang Xinma Pharmaceutical Co., Ltd. was found by the tax authority to have committed false invoicing and is required to pay back taxes and surcharges totaling 38.5051 million yuan.